Literature DB >> 2683362

Characterization of an HIV-2-related virus with a smaller sized extracellular envelope glycoprotein.

M A Rey1, B Krust, A G Laurent, D Guétard, L Montagnier, A G Hovanessian.   

Abstract

A new isolate of the human immunodeficiency virus (HIV) related to the HIV-2 strain was isolated from peripheral blood lymphocytes of an Ivory Coast patient with AIDS. This isolate referred to as HIV-2 EHO could be differentiated by its envelope precursor and external glycoprotein which are 20-kDa smaller than those of HIV-2 ROD isolate. Furthermore, the apparent molecular weight of the major core protein of HIV-2 EHO is 27 kDa instead of 26 kDa as in HIV-2 ROD isolate. In addition, the product of the vpx gene which is a characteristic feature of the HIV-2 strain, is 14 kDa in HIV-2 EHO compared with 16 kDa in HIV-2 ROD. In contrast to these, the envelope precursor of HIV-2 EHO forms a transient dimer its maturation as is the case for HIV-2 ROD. In both cases the transmembrane proteins are 36 kDa and exists as homodimers of 80 kDa. Endoglycosidase H digestion experiments indicated that the 20-kDa difference between the two HIV-2 isolates is not due to a difference in the number of N-linked oligosaccharide chains per polypeptide, since deglycosylated envelope precursors of HIV-2 ROD and EHO have an apparent molecular weight of 80 and 60 kDa, respectively. Partial proteolysis of the envelope precursors from the two isolates with Staphylococcus aureus V8 protease gave a distinct pattern of polypeptides. These results suggest that the differences between the external envelope proteins of the two HIV-2 isolates are due to their amino acid composition. Accordingly, polyclonal antibodies raised against HIV-2 ROD envelope do not recognize the corresponding envelope proteins of HIV-2 EHO by immunoblotting and immunoprecipitation assays. These data illustrate that analysis of viral proteins could be useful for a rapid characterization of new viral isolates and show the heterogeneity of HIV-2 isolates in West Africa.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2683362     DOI: 10.1016/0042-6822(89)90242-0

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Structural variability of env and gag gene products from a highly cytopathic strain of HIV-1.

Authors:  N Yahi; J Fantini; I Hirsch; J C Chermann
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE).

Authors:  D Schols; P Proost; J Van Damme; E De Clercq
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  A sorting motif localizes the foamy virus glycoprotein to the endoplasmic reticulum.

Authors:  P A Goepfert; K L Shaw; G D Ritter; M J Mulligan
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.

Authors:  Yuki Takamatsu; Debananda Das; Satoru Kohgo; Hironori Hayashi; Nicole S Delino; Stefan G Sarafianos; Hiroaki Mitsuya; Kenji Maeda
Journal:  Cell Chem Biol       Date:  2018-08-30       Impact factor: 8.116

5.  Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.

Authors:  R Pauwels; K Andries; Z Debyser; P Van Daele; D Schols; P Stoffels; K De Vreese; R Woestenborghs; A M Vandamme; C G Janssen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

6.  Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV action.

Authors:  Miguel Stevens; Christophe Pannecouque; Erik De Clercq; Jan Balzarini
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

7.  Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives.

Authors:  Miguel Stevens; Christophe Pannecouque; Erik De Clercq; Jan Balzarini
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.

Authors:  J Balzarini; M J Pérez-Pérez; A San-Félix; D Schols; C F Perno; A M Vandamme; M J Camarasa; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

9.  Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.

Authors:  Anneleen Hombrouck; Barbara Van Remoortel; Martine Michiels; Wim Noppe; Frauke Christ; Anders Eneroth; Britt Louise Sahlberg; Kurt Benkestock; Lotta Vrang; Nils Gunnar Johansson; Maria Letizia Barreca; Laura De Luca; Stefania Ferro; Alba Chimirri; Zeger Debyser; Myriam Witvrouw
Journal:  Antimicrob Agents Chemother       Date:  2008-06-09       Impact factor: 5.191

10.  Novel inhibitors of human immunodeficiency virus type 2 infectivity.

Authors:  Lauren B Beach; Jonathan M Rawson; Baek Kim; Steven E Patterson; Louis M Mansky
Journal:  J Gen Virol       Date:  2014-08-07       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.